Sean Stalfort's most recent trade in Acumen Pharmaceuticals Inc was a trade of 19,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 19,500 | 19,500 | - | - | Stock Option (right to buy) | |
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 12,800 | 185,124 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 113,246 | 113,246 | - | - | Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 56,623 | 1,155,224 | - | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Sean Stalfort | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 1,123,595 | 1,823,800 (7%) | 4% | - | Common Stock | |
| Verrica Pharmaceuticals Inc | Sean Stalfort | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 561,797 | 561,797 | - | - | Series B Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Sean Stalfort | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 561,797 | 561,797 | - | - | Series A Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Sean Stalfort | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Nov 2024 | 50,000 | 1,873,800 (7%) | 0% | 0 | Common Stock | |
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 98,440 | 98,440 | - | - | Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 49,220 | 1,098,601 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sean Stalfort | Director | Purchase of securities on an exchange or from another person at price $ 0.90 per share. | 16 Aug 2023 | 388,889 | 999,381 | - | 0.9 | 350,000 | Common Stock |
| Taysha Gene Therapies Inc | Sean Stalfort | Director | Purchase of securities on an exchange or from another person at price $ 0.90 per share. | 16 Aug 2023 | 388,889 | 884,290 | - | 0.9 | 350,000 | Common Stock |
| Taysha Gene Therapies Inc | Sean Stalfort | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Aug 2023 | 50,000 | 1,049,381 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 43,800 | 43,800 | - | - | Stock Option (right to buy) | |
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Verrica Pharmaceuticals Inc | Sean Stalfort | Director | Purchase of securities on an exchange or from another person at price $ 2.10 per share. | 05 Jul 2022 | 238,095 | 700,205 (2%) | 0% | 2.1 | 500,000 | Common Stock |
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | 06 Jul 2021 | 131,595 | 131,595 | - | - | Common Stock | ||
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | 06 Jul 2021 | 131,595 | 0 | - | - | Series B Preferred | ||
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | 06 Jul 2021 | 130,180 | 137,324 | - | - | Common Stock | ||
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | 06 Jul 2021 | 130,180 | 0 | - | - | Series A-1 Preferred | ||
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 06 Jul 2021 | 35,000 | 172,324 | - | 16 | 560,000 | Common Stock |
| Acumen Pharmaceuticals Inc | Sean Stalfort | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) |